Loading
CytoAgents
CytoAgents is a Pittsburgh company developing CTO1681, a tablet meant to prevent cytokine release syndrome, a dangerous immune over-reaction that can follow CAR-T cell therapy. It is being tested in an early trial.
Also called: CytoAgents, Inc.
Overview
CytoAgents, Inc., based in Pittsburgh, says it was founded in 2018 with a focus on cytokine release syndrome (CRS). Its compound CTO1681 is described by the company as an orally available, steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation; the website now also lists pulmonary arterial hypertension, asthma, atopic dermatitis and inflammation in the tumour microenvironment as indications. CytoAgents sponsors NCT05905328, a phase 1/2 trial of CTO1681 for the prevention and treatment of CRS in patients receiving CAR T-cell therapy, which ClinicalTrials.gov lists as recruiting. A 2026 National Cancer Institute SBIR award funds work on CTO1681 to prevent and mitigate CRS in people with multiple myeloma receiving CAR T-cell therapy.
Headquarters
Pittsburgh, PA, US
Scorecard
All companies#715of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 5R44CA295189-02: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy | 2026 | $936K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Founded
2018
Products
1Phase 2Oral small molecule
CTO1681 is a tablet from CytoAgents meant to prevent and treat cytokine release syndrome, an immune over-reaction that can follow CAR-T cell therapy for blood cancers.
Notes
- Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05905328 read on 4 November 2026. NCT05905328 is not yet a trial record in OnCo.
Connected
4cancers
fronts
drugs
Phase 2Oral small molecule
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
cytoagents.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/